GSK VS BSX Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

GSK
10/100

GSK returned 3.98% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BSX
100/100

BSX returned 26.68% in the last 12 months. Based on SPY's performance of -12.97%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

GSK
63/100

4 analysts offer 12-month price targets for GSK. Together, they have an average target of 0, the most optimistic target put GSK at 0 within 12-months and the most pessimistic has GSK at 0.

BSX
79/100

24 analysts offer 12-month price targets for BSX. Together, they have an average target of 57.93, the most optimistic target put BSX at 132 within 12-months and the most pessimistic has BSX at 43.

Technicals

GSK
10/100

GSK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

BSX
89/100

BSX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

GSK
66/100

GSK has missed earnings 3 times in the last 20 quarters.

BSX
26/100

BSX has missed earnings 4 times in the last 20 quarters.

Profit

GSK
72/100

Out of the last 20 quarters, GSK has had 20 profitable quarters and has increased their profits year over year on 7 of them.

BSX
72/100

Out of the last 20 quarters, BSX has had 18 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

GSK
56/100

GSK has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

BSX
48/100

BSX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

GSK

"Dividend" not found for GSK

BSX
10/100

BSX's most recent dividend was $0.01 per share, based on a share price of $53.85. It was a payout ratio of -8.24% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

GSK plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / GSK
Healthcare
Drug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Boston Scientific Corp. Summary

New York Stock Exchange / BSX
Healthcare
Medical - Devices
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.